Related Experiment Video
Updated: Oct 30, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Targeting CDK9 for the Treatment of Glioblastoma
Alice Ranjan1, Ying Pang1, Madison Butler1
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
Glioblastoma is the most common and aggressive primary malignant brain tumor, and more than two-thirds of patients with glioblastoma die within two years of diagnosis. The challenges of treating this disease mainly include genetic and microenvironmental features that often render the tumor resistant to treatments. Despite extensive research efforts, only a small number of drugs tested in clinical trials have become therapies for patients. Targeting cyclin-dependent kinase 9 (CDK9) is an emerging therapeutic approach that has the potential to overcome the challenges in glioblastoma management. Here, we discuss how CDK9 inhibition can impact transcription, metabolism, DNA damage repair, epigenetics, and the immune response to facilitate an anti-tumor response. Moreover, we discuss small-molecule inhibitors of CDK9 in clinical trials and future perspectives on the use of CDK9 inhibitors in treating patients with glioblastoma.
Insights
Targeting cyclin-dependent kinase 9 (CDK9) offers a promising strategy to combat glioblastoma, a deadly brain cancer. CDK9 inhibition impacts multiple cellular processes, potentially overcoming treatment resistance and improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glioblastoma is an aggressive primary brain tumor with a poor prognosis, often exhibiting resistance to current therapies.
- Treatment challenges stem from the tumor's complex genetic and microenvironmental characteristics.
- Limited therapeutic advancements highlight the need for novel treatment strategies.
Purpose of the Study:
- To explore the potential of targeting cyclin-dependent kinase 9 (CDK9) as a therapeutic strategy for glioblastoma.
- To elucidate the mechanisms by which CDK9 inhibition can induce an anti-tumor response.
- To review current CDK9 inhibitors in clinical trials and discuss future therapeutic perspectives.
Main Methods:
- Review of scientific literature on glioblastoma biology and therapeutic resistance.
- Analysis of the role of CDK9 in cellular processes relevant to cancer, including transcription, metabolism, DNA repair, epigenetics, and immune response.
- Survey of small-molecule CDK9 inhibitors currently in clinical development.
Main Results:
- CDK9 inhibition impacts key cellular pathways crucial for glioblastoma survival and proliferation.
- Targeting CDK9 demonstrates potential to overcome treatment resistance mechanisms.
- Several small-molecule CDK9 inhibitors are progressing through clinical trials for various cancers.
Conclusions:
- CDK9 inhibition represents a promising therapeutic avenue for glioblastoma treatment.
- Further research and clinical investigation of CDK9 inhibitors are warranted to improve glioblastoma patient outcomes.
- Targeting CDK9 offers a multifaceted approach to combatting this challenging malignancy.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity